Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OCS letter to industry

This article was originally published in The Gray Sheet

Executive Summary

Center for Devices and Radiological Health's office of compliance and surveillance sends letter to roughly 20,000 device manufacturers on Jan. 21 to clarify and solicit industry input on OCS initiatives. FDA says that it has advised field offices that FDA-483 citations "regarding the need for new 510(k)s or premarket approval application supplements because of changes to the device should not be made unless approved by CDRH." In addition, revision of the 510(k) regulations to require manufacturers to provide current information on device manufacturing and sterilizing locations "is under consideration," the letter says. The letter also explains OCS' "reference list," discusses fiscal year 1992 enforcement statistics, and provides updates on development of a revised good manufacturing practices regulation and enforcement of germicide manufacturers. Future letters may cover topics such as compliance policy guides under development and bioresearch monitoring....

You may also be interested in...



Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

US Medicare Agency Alters Payments For Use Of Telehealth Tech, Lab Specimen Collection For COVID-19

An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.

UsernamePublicRestriction

Register

MT000148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel